A novel fiber-optic based 0.014 '' pressure wire Designs of the OptoWire (TM), development phases, and the O-2 first-in-man results /

Objectives To review the technical limitations of available pressure-wires, present the design evolution of a nitinol fiber-optic pressure wire and to summarize the First-in-Man (FIM) O-2 pilot study results. Background Despite increasing use of physiology assessment of coronary lesions, several tec...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Ulacia Paola
Rimac Goran
Lalancette Sebastien
Belleville Claude
Mongrain Rosaire
Plante Sylvain
Ruzsa Zoltán
Matsuo Hitoshi
Bertrand Olivier F.
Dokumentumtípus: Cikk
Megjelent: 2022
Sorozat:CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS 99 No. 1
Tárgyszavak:
doi:10.1002/ccd.29321

mtmt:31661119
Online Access:http://publicatio.bibl.u-szeged.hu/24993
Leíró adatok
Tartalmi kivonat:Objectives To review the technical limitations of available pressure-wires, present the design evolution of a nitinol fiber-optic pressure wire and to summarize the First-in-Man (FIM) O-2 pilot study results. Background Despite increasing use of physiology assessment of coronary lesions, several technical limitations persist. We present technical details, design evolution and early clinical results with a novel 0.014 '' nitinol fiber-optic based pressure-wire. Methods and Results The 0.014' OptoWire (TM) (Opsens Medical, Quebec, Canada) was designed to combine improved handling properties compared to standard pressure-wires and to offer extremely reliable pressure recording and transmission due to fiber-optic properties compared to piezo-electric sensors and electrical wires. In vitro assessment showed that OptoWire (TM) steerability, pushability and torquability properties were closer to regular PCI wires than standard electrical pressure wires. In the First-in-Man O(2)study, 60 patients were recruited at 2 centers in Canada. A total of 103 lesions were assessed with the OptoWire (TM) and OptoMonitor (TM), 75 lesions at baseline and 28 lesions post-PCI (without disconnection). In all crossed lesions (n = 100, 97%), mean Pd/Pa and FFR could be adequately measured. In 11 cases assessed successively with OptoWire (TM) and Aegis (TM) (Abbott Vascular, USA) bland-Altman analysis showed a mean difference of 0.002 +/- 0.052 mmHg (p = .91) for Pd/Pa and 0.01 +/- 0.06 for FFR calculation (p= .45). There was no device-related complication. Upon these initial results, several design changes aimed to improve overall performance including torquability, stiffness, resistance to kink and pressure drift were completed. Conclusion The novel 0.014 '' fiber-optic OptoWire (TM) provides superior wire handling with reduced risk of pressure drift allowing reliable pre- and post-PCI physiology assessment.
Terjedelem/Fizikai jellemzők:59-67
ISSN:1522-1946